Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Randomized Phase III Study of Watchful Waiting Vs. Rituximab As First-Line Treatment in Patients with Advanced Stage Low Tumor Burden Follicular Lymphoma: JCOG1411/Flora Study

Blood (2024) 144 (Supplement 1): 338.

https://doi.org/10.1182/blood-2024-199868

Published: 2024

Journal Articles

AML-Mrg Mutation Spectrum and Its Prognosis: A Japanese Multicenter Study HM01-02 Analysis with Full Analysis Sets

Blood (2024) 144 (Supplement 1): 6123.

https://doi.org/10.1182/blood-2024-202327

Published: 2024

Journal Articles

Combination of Low White Blood Cell Count and Impaired Renal Function Is a Risk Factor for Higher Concentrations of Venetoclax and Prolonged Neutropenia in AML Patients with Venetoclax Combined Regimen: Real World Experience in the Japanese Cohort

Minoru Kanaya, Yuji Mukai, Mirei Kobayashi, Sayaka Kajikawa, Toma Suzuki, Emi Yokoyama, Koh Izumiyama, Makoto Saito, Masanobu Morioka, Akio Mori, Toshihiro Matsukawa, Masahiro Onozawa, Goichi Yoshimoto, Mitsuru Moriyama, Sunggi Chi, Takanori Teshima, Yosuke Minami, Masato Honmma, Takeshi Kondo

Blood (2024) 144 (Supplement 1): 2930.

https://doi.org/10.1182/blood-2024-198943

Published: 2024

Journal Articles

Ponatinib Monotherapy after Combination with Chemotherapy in Patients with Newly Diagnosed Ph+ ALL: Post Hoc Subgroup Analysis of the Phase 3 Phallcon Study

Blood (2024) 144 (Supplement 1): 2821.

https://doi.org/10.1182/blood-2024-208504

Published: 2024

Journal Articles

Clinical Significance of Mutant TP53 Alleles and Functions in Acute Myeloid Leukemia: HM-Screen-Japan 01/02 Study

Kensuke Kojima, Fumiya Ogasawara, Sunggi Chi, Kentaro Fukushima, Yosuke Minami, Tomoaki Ueda

Blood (2024) 144 (Supplement 1): 2908.

https://doi.org/10.1182/blood-2024-194167

Published: 2024

Journal Articles

Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population

Blood (2023) 142 (Supplement 1): 4536.

https://doi.org/10.1182/blood-2023-186854

Published: 2023

Journal Articles

Practical and Flexible Genome Profiling Study Using the Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System: HM-Screen-JAPAN02

Naoko Hosono, Takahiro Yamauchi, Chi Sung-Gi, Hironori Arai, Kentaro Fukushima, Daisuke Ikeda, Satoshi Iyama, Akihiko Gotoh, Takayuki Ikezoe, Chikashi Yoshida, Goichi Yoshimoto, Junya Kanda, Naoto Takahashi, Emiko Sakaida, Kensuke Usuki, Yosuke Minami

Blood (2023) 142 (Supplement 1): 2279.

https://doi.org/10.1182/blood-2023-184546

Published: 2023

Journal Articles

Impact of Mutations in Blood Cancer-Related Genes on Clinical Outcomes in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Tyrosine Kinase Inhibitors (TKIs) in the Ascembl Trial

Susan Branford, Andreas Hochhaus, Michael Mauro, Yosuke Minami, Delphine Rea, Carla Maria Boquimpani De Moura Freitas, Pablo Serrano-Fernandez, Vanessa Obourn, Andreas Bruederle, Noemi Espurz, Timothy P Hughes

Blood (2023) 142 (Supplement 1): 449.

https://doi.org/10.1182/blood-2023-187636

Published: 2023

Journal Articles

Detection of Chip Variants Based on a Large Japanese WGS Data

Sunggi Chi, Ikuko Motoike, Katsuya Tsuchihara, Kinuko Ohneda, Yosuke Minami, Riu Yamashita

Blood (2023) 142 (Supplement 1): 5596.

https://doi.org/10.1182/blood-2023-185202

Published: 2023

Journal Articles

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph+ ALL: Subgroup Analysis of the Phase 3 Phallcon Study

Blood (2023) 142 (Supplement 1): 2871.

https://doi.org/10.1182/blood-2023-179537

Published: 2023

Journal Articles

NGS Profile and the Mathematical Prediction Model for Venetoclax Combination Therapy in HM-Screen-Japan 02 Study

Tomoaki Ueda, Kentaro Fukushima, Naoki Hosen, Sunggi Chi, Hiroshi Haeno, Goichi Yoshimoto, Hironori Arai, Daisuke Ikeda, Kensuke Usuki, Naoto Takahashi, Naoko Hosono, Takahiro Yamauchi, Takeshi Kondo, Kazuhito Yamamoto, Junya Kuroda, Yosuke Minami

Blood (2023) 142 (Supplement 1): 5761.

https://doi.org/10.1182/blood-2023-180339

Published: 2023

Journal Articles

Preclinical Translational Research Suggests a Clinical Trial Strategy for a Novel MALT1 Inhibitor ONO-7018/CTX-177 Against Malignant Lymphomas

Daisuke Morishita, Akio Mizutani, Hiroko Yamakawa, Yasuyoshi Arikawa, Hirokazu Tozaki, Takuro Kameda, Ayako Kamiunten, Keisuke Kataoka, Akinori Yoda, Yotaro Ochi, Kotaro Shide, Koji Izutsu, Yosuke Minami, Kazuya Shimoda, Seishi Ogawa

Blood (2022) 140 (Supplement 1): 8874–8875.

https://doi.org/10.1182/blood-2022-171019

Published: 2022

Journal Articles

A Practice-Oriented Genome Profiling Study with the Novel Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System : HM-Screen-JAPAN02

Blood (2022) 140 (Supplement 1): 10722–10724.

https://doi.org/10.1182/blood-2022-159351

Published: 2022

Journal Articles

Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study

Timothy Hughes, Delphine Rea, Carla Boquimpani, Yosuke Minami, Michael Mauro, Jorge E. Cortes, Jane F. Apperley, Valentín García Gutiérrez, Shruti Kapoor, Alex Allepuz, Sarah Quenet, Yifan Zhang, Andreas Hochhaus

Blood (2022) 140 (Supplement 1): 6757–6759.

https://doi.org/10.1182/blood-2022-169110

Published: 2022

Journal Articles

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Blood (2021) 138 (21): 2031–2041.

https://doi.org/10.1182/blood.2020009984

Published: 2021

Includes: Supplemental data

Journal Articles

Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks

Blood (2021) 138 (Supplement 1): 310.

https://doi.org/10.1182/blood-2021-152561

Published: 2021

Journal Articles

Clinical Significance of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01

Blood (2021) 138 (Supplement 1): 2313.

https://doi.org/10.1182/blood-2021-146796

Published: 2021

Journal Articles

Genomic Analysis of NPM1 Mutation and KMT2A ( MLL )-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01

Blood (2021) 138 (Supplement 1): 4460.

https://doi.org/10.1182/blood-2021-149425

Published: 2021

Journal Articles

Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis

Blood (2021) 138 (Supplement 1): 4447.

https://doi.org/10.1182/blood-2021-149801

Published: 2021

Journal Articles

Genomic Analysis Focusing on RUNX1-RUNX1T1 in Japanese Patients with AML: HM-Screen-Japan 01

Blood (2021) 138 (Supplement 1): 4464.

https://doi.org/10.1182/blood-2021-148492

Published: 2021

NARROW

Randomized Phase III Study of Watchful Waiting Vs. Rituximab As First-Line Treatment in Patients with Advanced Stage Low Tumor Burden Follicular Lymphoma: JCOG1411/Flora Study

AML-Mrg Mutation Spectrum and Its Prognosis: A Japanese Multicenter Study HM01-02 Analysis with Full Analysis Sets

Combination of Low White Blood Cell Count and Impaired Renal Function Is a Risk Factor for Higher Concentrations of Venetoclax and Prolonged Neutropenia in AML Patients with Venetoclax Combined Regimen: Real World Experience in the Japanese Cohort

Ponatinib Monotherapy after Combination with Chemotherapy in Patients with Newly Diagnosed Ph+ ALL: Post Hoc Subgroup Analysis of the Phase 3 Phallcon Study

Clinical Significance of Mutant TP53 Alleles and Functions in Acute Myeloid Leukemia: HM-Screen-Japan 01/02 Study

Practical and Flexible Genome Profiling Study Using the Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System: HM-Screen-JAPAN02

Impact of Mutations in Blood Cancer-Related Genes on Clinical Outcomes in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Tyrosine Kinase Inhibitors (TKIs) in the Ascembl Trial

Detection of Chip Variants Based on a Large Japanese WGS Data

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph+ ALL: Subgroup Analysis of the Phase 3 Phallcon Study

NGS Profile and the Mathematical Prediction Model for Venetoclax Combination Therapy in HM-Screen-Japan 02 Study

Preclinical Translational Research Suggests a Clinical Trial Strategy for a Novel MALT1 Inhibitor ONO-7018/CTX-177 Against Malignant Lymphomas

A Practice-Oriented Genome Profiling Study with the Novel Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System : HM-Screen-JAPAN02

Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks

Clinical Significance of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01

Genomic Analysis of NPM1 Mutation and KMT2A ( MLL )-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01

Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis

Genomic Analysis Focusing on RUNX1-RUNX1T1 in Japanese Patients with AML: HM-Screen-Japan 01

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only